The IRDiRC Companies Constituent Committee (CCC) is pleased to welcome PacBio as its newest member, represented by Nina Gonzaludo, Global Lead Human Genomics, based in the USA. PacBio is a global leader in long-read sequencing […]
Read More
The International Rare Diseases Research Consortium will be at the forefront of discussions at World Orphan Drug Congress USA 2026, highlighting innovations in rare disease research, personalized therapies, and sustainable approaches to genetic […]
Read More
As part of the Horizon Europe project RealiseD, a short survey is being conducted to better understand how clinical sites identify, approach, and enrol patients with rare diseases. Investigators, study nurses, […]
Read More
IRDiRC’s Patient Advocacy Constituent Committee member, EURORDIS-Rare Diseases Europe is organizing a new edition of the European Conference on Rare Diseases & Orphan Products (ECRD), the largest patient-led policy-shaping event on rare […]
Read More
A new IRDiRC feature article published in Drug Discovery Today provides a comprehensive assessment of non-oncology orphan drug development, focusing on productivity and the probability of success for therapies targeting rare diseases outside […]
Read More
A global community of clinicians, patient leaders, regulators and researchers met in Heidelberg (Germany) and online for the second International Conference on Clinical Research Networks (CRNs), organised by the European […]
Read MoreIRDiRC is pleased to announce that COMBINEDBrain, represented by Terry Jo Bichell (CEO), has joined the IRDiRC Patient Advocacy Constituent Committee (PACC). The Consortium for Outcome Measures and Biomarkers for […]
Read More
Want to stay informed about the latest breakthroughs, global initiatives, and collaborative efforts shaping the future of rare disease research? Join the International Rare Diseases Research Consortium (IRDiRC) community by subscribing to […]
Read More
A new analysis of orphan drug approvals across six global regulatory regions highlights significant delays in access to innovative therapies for people living with rare diseases. The study, conducted by […]
Read MoreThe International Rare Diseases Research Consortium (IRDiRC) is pleased to announce the appointment of Shekhar Natarajan (Vice President, Head of EU and International Regulatory Affairs at Dyne Therapeutics, USA), as Chair, and Diana […]
Read More